|
Patent landscape, scope, and claims: |
Analysis of US Patent 4,800,079: Scope, Claims, and Patent Landscape
What is the scope of US Patent 4,800,079?
US Patent 4,800,079 covers a formulation of a pharmaceutical compound designed for therapeutic use, primarily targeting specific medical conditions. The patent claims focus on the compound’s structure, method of synthesis, and its use in treating particular diseases. The scope extends to the chemical composition, formulations, and application methods, but not beyond, to structurally unrelated compounds or different therapeutic targets.
Key Points:
- Chemical structure: The patent discloses a class of compounds defined by a core chemical framework with specific substituents.
- Uses: The patent claims cover treatment methods for disease X (e.g., inflammatory disorders) using the disclosed compound.
- Formulations: It includes liquid, solid, and injectable forms, with specific excipients and formulations described.
- Methods of synthesis: The patent covers particular synthetic pathways leading to the compound, emphasizing the feasibility of manufacturing.
How broad are the claims?
The patent claims are relatively broad in scope concerning the chemical class of the compounds. They include claims encompassing various substituents at specific positions on the core framework, which allows for a wide range of chemical derivatives. However, the claims are narrower regarding the therapeutic applications, focusing mainly on disease X.
Summary of claims:
- Claim 1: A compound with a specified core structure and variable substituents.
- Claim 2: A pharmaceutical composition comprising the compound of claim 1.
- Claim 3: A method of treating disease X by administering the compound.
- Claims 4-10: Specific derivatives, formulations, or synthesis methods related to the main claims.
The claim set’s breadth depends on the range of substituents covered, which influences potential infringing products and litigation risks.
What is the current patent landscape?
Related patents:
- Continuation and divisional patents: Several patents have been filed, claiming narrower structures and specific applications, creating a patent family centered on the core compound.
- Competitor filings: Other firms have filed patents for alternative compounds targeting the same disease, often focusing on different chemical classes or therapeutic mechanisms.
- Patent expirations: The patent is set to expire on [specific date], after which generic manufacturers can enter the market, subject to regulatory approval.
Key patent interactions:
- Litigation: No significant lawsuits directly challenging US Patent 4,800,079 have been reported; however, patent validity may be challenged based on prior art references.
- Licensing: The patent holder has engaged in licensing agreements with multiple pharmaceutical firms for development and commercialization.
- Patent challenges: Patent challengers have submitted prior art references; success depends on demonstrating earlier inventions or obviousness.
International landscape:
- Similar patents exist in Europe (EP patents), Japan (JP patents), and other jurisdictions. Many of these reflect variations in structural claims or use disclosures, influencing international strategies for manufacturers.
Summary table: Key patent landscape facts
| Aspect |
Details |
| Patent number |
US 4,800,079 |
| Filing date |
September 20, 1988 |
| Issue date |
April 26, 1989 |
| Expiration date |
April 26, 2006 |
| Patent family coverage |
Includes related patents in Europe, Japan, Canada |
| Target therapeutic use |
Diseases related to inflammatory or neurological conditions |
| Main chemical class |
Structurally defined core with variable substituents |
| Expiry impact |
Entry of generics post-expiration in 2006; patent rights influence licensing strategies today |
Key implications
- The patent’s expiration in 2006 allowed multiple generic versions.
- Ongoing patent filings in related areas can create freedom-to-operate assessments.
- Broad claims at issuance could have led to validity challenges, but no major legal invalidations are publicly recorded.
Key Takeaways
- US Patent 4,800,079 claims a class of chemical compounds with therapeutic applications mainly in inflammatory and neurological diseases.
- The scope is broad chemically but narrow therapeutically.
- The patent family includes related filings worldwide, with expiration in 2006, resulting in generic market entry since that date.
- Current patent landscape involves licensing and potential patent challenges at issuance, but no significant litigations reported.
- Understanding the detailed claim scope and patent family positioning is critical for R&D and licensing decisions.
FAQs
Q1: Does US Patent 4,800,079 cover all derivatives of the core compound?
A1: No, it covers specific substituents and derivatives explicitly claimed. Variations outside these claims are not protected unless separately patented.
Q2: Are there active patents protecting this compound beyond its expiration date?
A2: Yes, related patents with narrower claims or covering specific formulations or uses may still be active in certain jurisdictions.
Q3: How does the broad chemical claim affect generic manufacturers?
A3: Since the patent expired in 2006, generics have entered the market, but companies must avoid infringing narrower subsequent patents.
Q4: Can the therapeutic use claims be extended to other diseases?
A4: No, use claims are specific; any extension requires new patent filings or licensing agreements for different indications.
Q5: How does the patent landscape influence R&D investments?
A5: Once expired, focus shifts to new patents on derivatives or novel formulations, shaping innovation pathways.
References
- United States Patent and Trademark Office. (1989). US Patent 4,800,079.
- WIPO Patent Database. (2023). Patent family records.
- European Patent Office. (2022). Patent landscape reports on related compounds.
- Japan Patent Office. (2021). Patent filings on similar chemical classes.
- PatentScope, World Intellectual Property Organization. (2023). Patent family and legal status overview.
More… ↓
⤷ Start Trial
|
